| abstract |
Pharmaceutical compositions of the invention comprise TDP-43 binding agents having a disease-modifying action in the treatment of diseases associated with TDP-43 that include ALS, FTLD, CTE, hippocampal sclerosis of aging (CARTS), Alzheimers disease, and Alzheimers disease related disorder, and disease that involve excess amounts of TDP-43 in the cytosol. |